Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial., PMID:40389374
Protocol for in-plate staining of clinical peripheral blood mononuclear cell samples for high-throughput analysis via spectral flow cytometry., PMID:40347474
Clinico-genomic features predict distinct metastatic phenotypes in cutaneous melanoma., PMID:39975034
Cigarette Smoking and Symptom Burden: Baseline Results From Nine ECOG-ACRIN Cancer Clinical Trials., PMID:39746495
Second-line systemic treatment for metastatic colorectal cancer: A systematic review and Bayesian network meta-analysis based on RCT., PMID:39715232
Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab., PMID:39699928
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047., PMID:39671533
Protein kinase inhibitors as targeted therapy for glioblastoma: a meta-analysis of randomized controlled clinical trials., PMID:39637954
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients., PMID:39612757
Stratified analysis identifies HIF-2α as a therapeutic target for highly immune-infiltrated melanomas., PMID:39554029
Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma., PMID:39504576
A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer., PMID:39348472
Craters on the melanoma surface facilitate tumor-immune interactions and demonstrate pathologic response to checkpoint blockade in humans., PMID:39345527
Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study., PMID:39209782
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab., PMID:39209453
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer., PMID:39190534
Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor., PMID:38990554
Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma., PMID:38982051
Evaluating the efficacy and safety of trebananib in treating ovarian cancer and non-ovarian cancer patients: a meta-analysis and systematic review., PMID:38970210
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study., PMID:38898592
Transmural Flow Upregulates PD-L1 Expression in Microvascular Networks., PMID:38696611
Angiopoietin-2 and the Vascular Endothelial Growth Factor Promote Migration and Invasion in Hepatocellular Carcinoma- and Intrahepatic Cholangiocarcinoma-Derived Spheroids., PMID:38255193
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment., PMID:38236249
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery., PMID:38109213
The effect of neighborhood socioeconomic disadvantage on smoking status, quit attempts, and receipt of cessation support among adults with cancer: Results from nine ECOG-ACRIN Cancer Research Group trials., PMID:37795845
A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma., PMID:37359242
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial., PMID:37167764
Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma., PMID:37040087
Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma., PMID:37037616
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)., PMID:36927527
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease., PMID:36706355
Germline variants associated with toxicity to immune checkpoint blockade., PMID:36526723
Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors., PMID:36179682
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors., PMID:35940825
Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit., PMID:35797509
Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors., PMID:35663537
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial., PMID:35662283
Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males., PMID:35659704
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial., PMID:35414591
A comprehensive systematic review and network meta-analysis: the role of anti-angiogenic agents in advanced epithelial ovarian cancer., PMID:35264616
Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors., PMID:35264434
Reply to T. Olivier et al., PMID:35258992
Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary., PMID:35074904
Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report., PMID:35070436
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial., PMID:35033226
Efficacy and Safety of Bevacizumab Combined with Other Therapeutic Regimens for Treatment of Recurrent Glioblastoma: A Network Meta-analysis., PMID:34973444
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial., PMID:34772758
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006., PMID:34571336
Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition., PMID:34561127
Utility of Liver Biopsy in Diagnosis and Management of High-grade Immune Checkpoint Inhibitor Hepatitis in Patients With Cancer., PMID:34554206
For research use only. Not for human or drug use.
